PVX108 for Peanut Allergy
Aravax is building a pipeline of immunotherapy candidates to tackle a range of food allergy indications
We are starting with peanut allergy which is one of the most common causes of severe and fatal allergic reactions related to food.
Our lead product PXV108 is currently being evaluated in phase 2 clinical trials.
PVX108 – Peanut Allergy
PVX108 is being developed as a safe and convenient-to-use therapy to reduce the risk of severe allergic reactions upon accidental exposure to peanuts.
PVX108 Product Description
Composed of seven proprietary peptides. Each peptide represents one or more immuno-dominant T cell epitopes from major peanut allergens and is designed to avoid triggering acute allergic reactions during treatment. PVX108 is synthesised, characterised and manufactured to pharmaceutical quality standards.
The product does not contain whole allergens or extracts.
PVX108 Rationale
Precisely targets the T cells responsible for peanut allergy, with the aim of safely retraining the immune system to restore and maintain tolerance to peanut, to reduce the risk of anaphylaxis upon accidental peanut exposure.
Patient-friendly Administration
Intradermal once per month administration. Does not require dose escalation or burdensome measures to manage risks of adverse reactions to therapy.
Clinical Status
Fully enrolled international Phase 2 clinical trial of PVX108 in peanut allergic adolescents and children is ongoing under an IND at clinics in the United States and Australia.
| Learn more about our ongoing phase 2 trials | Learn more about the positive safety results from our completed PVX108 Phase 1 clinical trial |
PVX108 is an investigational drug product
PVX108 is undergoing clinical studies to evaluate the safety and effectiveness in humans. It has not received marketing authorization or approval by any regulatory agency, including the US Food and Drug Administration, or the Australian Therapeutic Goods Administration and the European Medicines Agency.
